Streetwise Reports' Article Archives — September 2023 back to current month (13)

New Contract Adding Thousands of Patients to Telehealth Platform (09/27/2023)

This telehealth company has signed a contract with a physician network to add as many as 100,000 patients to its platform. Find out why the CEO says it is in a period of rapid growth.

more>

Biopharma Co. Adds CTO to Team (09/21/2023)

This newest member brings with him extensive experience in protein development and manufacturing, noted an Oppenheimer report.

more>

Trial Results Validate New Drug-Delivering Nasal Implant (09/20/2023)

This product candidate presents a compelling approach to treating post-surgery chronic rhinosinusitis patients, noted an H.C. Wainwright & Co. report.

more>

Biotech Co. Makes Strides on Three Fronts (09/19/2023)

This Canadian firm sold assets, launched an equity raise and filed a clinical trial application for its lead psychedelic-assisted psychotherapy program, noted a Stifel report.

more>

Telehealth Co. Signs Contract With Client in Eight States (09/13/2023)

This telehealth company has signed a new contract for its remote patient monitoring platform to be used by a leading healthcare company with dozens of locations in eight states.

more>

Telehealth Co. Expands Platform To Cover Pediatric Patients (09/08/2023)

This telehealth company is expanding its platform to cover remote monitoring for pediatric patients with diabetes and other eligible conditions. Find out why one analyst says this company's stock is gathering momentum.

more>

Co. Reaches Major Milestone With Novel Drug (09/07/2023)

The biopharma initiated enrollment of a targeted 420 patients for one of its Phase 3 clinical trials evaluating its new cardiac myosin inhibitor, noted an H.C. Wainwright & Co. report.

more>

Cryoablation System Gets Approved in Brazil (09/07/2023)

The product developer expects to generate US$6.6 million in sales of this medical device in Brazil over the next five years, noted an H.C. Wainwright & Co. report.

more>

After Seeing 86% Success Rate in Phase 2, Biotech Co. Moves to Phase 3 for AUD Treatment (09/06/2023)

Awakn Life Sciences has applied for Phase 3 of clinical trials after the success of Phase 2. Read on to see what this company plans for its flagship new drug.

more>

FTC Settles Suit, Potentially Averting Further Hurdles (09/06/2023)

McAlinden Research shares a deep dive into a market driver with alpha-generating potential.

more>

Contract Adding Thousands of Patients to Co.'s Telehealth Platform (09/05/2023)

This telehealth company has signed a new contract with a Texas respiratory clinic that is expected to add 10,000 new patients to its iUGO platform by mid-2024. Read to see why one analyst believes this stock is a Buy.

more>

New Vaccine for Chikungunya Shown To Be Safe in Youths (09/01/2023)

The company behind the vaccine plans to use the safety data to support approvals in the U.S., European Union and Brazil, noted an H.C. Wainwright & Co. report.

more>

Approved Drug for Skin Condition Shown Safe at Higher Dose (09/01/2023)

Based on these positive Phase 1 trial results in actinic keratosis, the biopharma developer will seek label expansion in the U.S., noted a ROTH Capital Partners report.

more>

More Archives

2024Jan

2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Notable Quotes